Edwards Lifesciences Corporation $EW Shares Bought by GDS Wealth Management

Key Points

• GDS Wealth Management increased its stake in Edwards Lifesciences Corporation by 8.2% by purchasing an additional 15,606 shares, bringing their total holdings to 206,619 shares valued at approximately $14.98 million.
• Analysts have recently upgraded their ratings for Edwards Lifesciences, with price targets ranging from $84.00 to $95.00. The company currently holds an average rating of "Moderate Buy."
• Edwards Lifesciences reported $1.53 billion in revenue for the last quarter, exceeding analysts' expectations and showing an 11.9% increase year-over-year.

GDS Wealth Management raised its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 8.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 206,619 shares of the medical research company's stock after purchasing an additional 15,606 shares during the quarter. GDS Wealth Management's holdings in Edwards Lifesciences were worth $14,976,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Edwards Lifesciences during the 1st quarter worth $26,000. Vega Investment Solutions purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $27,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $27,000. Global X Japan Co. Ltd. increased its stake in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC increased its stake in shares of Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $0.4490 during trading on Monday, reaching $81.3810. The company's stock had a trading volume of 943,127 shares, compared to its average volume of 4,496,353. The business has a 50 day moving average price of $77.58 and a 200-day moving average price of $74.72. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $47.78 billion, a P/E ratio of 11.70, a price-to-earnings-growth ratio of 3.95 and a beta of 1.08. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on EW. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Wells Fargo & Company increased their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Finally, BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. The trade was a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,584 shares of company stock worth $1,897,762 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.